The leading stocks of 2019 thus far are determined by strong backstories, competent results, or simply an outrageous amount of widespread review.
Array Biopharma (ARRY)
Recently, in May, ARRY stock dramatically increased when a therapy promised a treatment for advanced melanoma.
Sinclair Broadcast Group (SBGI)
Sinclair shares has started great this year and it might be one of the few traditional television companies who would get through the cord-cutting phenomenon.
Iovance Biotherapeutics (IOVA)
Several investors are looking forward about Lifileucel as a treatment for melanoma. It is currently in the last phase trials and is looking very promising thus far.
Guardant Health (GH)
GH is the developer of several highly-focused oncology diagnostic test. And it is not only one of the best stocks of this year, it has also been one of the hottest IPOs. Its shares already up on an astounding 300% in early October when it went public, and increased by more than 100% by the end of 2018.
Mirati Therapeutics (MRTX)
The highly-anticipated drug is Sitavatinib, which is an immuno-oncology agent that whenever used with an anti-PD-1 checkpoint inhibitor drug Opdivo, shows likelihood of being able to treat non-small-cell lung cancer.
Avalara is a software company who takes pride in its sales tax calculation tool. With stable operating earnings, AVLR is up 110% so far this year, therefore including it in 2019’s leading stocks.
Despite the loss that took place in 2018, SNAP has recovered with the aid of increased number of daily users logging into the app. User growth could indicate a brighter future ahead of Snap, especially now that the company is working on a huge project on how music can be used in the app.
Sea Limited (SE)
Sea Limited is a digital entertainment provider in Asia. However, Sea is popular for its digital wallet app called AirPay. Sales are foreseen to rise by nearly 100% this year, and increase another 40% in the following year.
Spark Therapeutics (ONCE)
In late February, ONCE stocks has dramatically soared when a huge drug company Roche presented a very generous acquisition offer. While the offer hasn’t been finalized yet, it expects the offer to be all set before the end of the month.
This year’s biggest winner is Roku with shares up nearly 200% in just five months. A 41% increase in this year’s sales are highly-anticipated to be followed by a 33% growth the following year.